Krieger J P, Welsch C, Giesen-Crouse E, Schmidt M, Imbs J L
Institut de Pharmacologie, UA 589 CNRS, Strasbourg, France.
Arch Mal Coeur Vaiss. 1987 Jun;80(6):862-5.
On the isolated perfused rat kidney, angiotensin-converting-enzyme activity was evaluated by two approaches: one, biochemical, through the measurements of the enzymatic activity on renal homogenate, the other, pharmacological, through the vasoconstrictor response to angiotensin I. Renal tissue angiotensin-converting-enzyme activity was not modified by setting the kidney under perfusion with a modified Krebs-Henseleit solution but was inhibited after addition of captopril into the perfusion medium (10(-5) M, 100 p. 100 inhibition) or after pretreatment of the animals with ramipril (10 mg/kg/day over 3 weeks, per os, 60 p. 100 inhibition). On the isolated perfused rat kidney, angiotensin I and angiotensin II induced a concentration dependent renal vasoconstriction (EC50 = 1.05 +/- 0.18 X 10(-8) and 0.11 +/- 0.05 X 10(-8) M) which was competitively antagonized by saralasin, an angiotensin II receptor antagonist. Addition of angiotensin-converting-enzyme inhibitors to the perfusion medium (captopril or ramiprilat, 10(-5) M) or pretreatment of the animals with ramipril (50 mg/kg, i.p. the day before or 10 mg/kg/day over 3 weeks, per os) only shifted the angiotensin I concentration-response curve to the right by a factor 3 to 4. The residual vasoconstrictor effect of angiotensin I was abolished by 10(-5) M saralasin and remains linked to a local generation of angiotensin II. Our results suggest that, on the isolated perfused rat kidney, besides the angiotensin-converting-enzyme, an iso-enzyme may also be able to generate angiotensin II.
在离体灌注大鼠肾脏上,通过两种方法评估血管紧张素转换酶活性:一种是生化方法,通过测量肾匀浆中的酶活性;另一种是药理学方法,通过对血管紧张素I的血管收缩反应。用改良的克雷布斯-亨泽莱特溶液灌注肾脏,肾组织血管紧张素转换酶活性未改变,但在灌注介质中加入卡托普利(10⁻⁵ M,100%抑制)或用雷米普利预处理动物(10 mg/kg/天,持续3周,口服,60%抑制)后,该活性受到抑制。在离体灌注大鼠肾脏上,血管紧张素I和血管紧张素II诱导浓度依赖性肾血管收缩(EC50 = 1.05 ± 0.18×10⁻⁸和0.11 ± 0.05×10⁻⁸ M),这被血管紧张素II受体拮抗剂沙拉新竞争性拮抗。向灌注介质中加入血管紧张素转换酶抑制剂(卡托普利或雷米普利拉,10⁻⁵ M)或用雷米普利预处理动物(50 mg/kg,腹腔注射,前一天或10 mg/kg/天,持续3周,口服)仅使血管紧张素I浓度-反应曲线右移3至4倍。血管紧张素I的残余血管收缩作用被10⁻⁵ M沙拉新消除,且仍与局部生成血管紧张素II有关。我们的结果表明,在离体灌注大鼠肾脏上,除血管紧张素转换酶外,一种同工酶也可能能够生成血管紧张素II。